Latest filings (excl ownership)
PRE 14A
Preliminary proxy
16 Apr 24
8-K
Departure of Directors or Certain Officers
15 Apr 24
8-K
Termination of a Material Definitive Agreement
22 Mar 24
424B5
Prospectus supplement for primary offering
26 Feb 24
424B5
Prospectus supplement for primary offering
23 Feb 24
8-K
Amendment No. 1 to the Open Market Sale Agreementsm
23 Feb 24
S-8
Registration of securities for employees
22 Feb 24
10-K
2023 FY
Annual report
22 Feb 24
8-K
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress
22 Feb 24
8-K
Regulation FD Disclosure
1 Feb 24
8-K
Intellia Therapeutics Highlights its Three-Year Strategic Priorities and Anticipated 2024 Key Milestones
4 Jan 24
8-K
Departure of Directors or Certain Officers
6 Dec 23
S-3ASR
Automatic shelf registration
24 Nov 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Intellia Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
9 Nov 23
8-K
Intellia Presents New Interim Data from the Ongoing Phase 1 Study of NTLA-2001 at the 4th International ATTR Amyloidosis Meeting
2 Nov 23
8-K
Intellia Therapeutics Announces FDA Clearance of
18 Oct 23
8-K
Regeneron and Intellia Announce Expanded Research Collaboration
3 Oct 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
8-K
Intellia Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress
3 Aug 23
8-K
Amendments to Articles of Incorporation or Bylaws
16 Jun 23
8-K
Intellia Therapeutics Announces New Positive Clinical Data from Phase 1 Study of
12 Jun 23
DEFA14A
Additional proxy soliciting materials
5 Jun 23
8-K
Departure of Directors or Certain Officers
5 Jun 23
10-Q
2023 Q1
Quarterly report
4 May 23
8-K
Intellia Therapeutics Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress
4 May 23
DEFA14A
Additional proxy soliciting materials
1 May 23
DEF 14A
Definitive proxy
1 May 23
ARS
2022 FY
Annual report to shareholders
18 Apr 23
PRE 14A
Preliminary proxy
18 Apr 23
8-K
Intellia Therapeutics Names Bill Chase to its Board of Directors
17 Apr 23
8-K
Departure of Directors or Certain Officers
24 Mar 23
8-K
Intellia Therapeutics Announces FDA Clearance of Investigational New Drug
2 Mar 23
S-8
Registration of securities for employees
23 Feb 23
10-K
2022 FY
Annual report
23 Feb 23
8-K
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Company Progress
23 Feb 23
8-K
Intellia Therapeutics Highlights Strategic Priorities and Anticipated 2023 Key Milestones
5 Jan 23
8-K
Entry into a Material Definitive Agreement
1 Dec 22
424B5
Prospectus supplement for primary offering
1 Dec 22
8-K
Intellia Therapeutics Presents New Interim Data
14 Nov 22
Latest ownership filings
3
Michael P Dube
22 Apr 24
4
Laura Sepp-Lorenzino
5 Mar 24
4
JAMES BASTA
5 Mar 24
4
Derek Hicks
5 Mar 24
4
Eliana Clark
5 Mar 24
4
JOHN M LEONARD
5 Mar 24
4
David Lebwohl
5 Mar 24
4
Glenn Goddard
5 Mar 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
ARK Investment Management LLC
29 Jan 24
SC 13G/A
STATE STREET CORP
24 Jan 24
4
Laura Sepp-Lorenzino
10 Jan 24
SC 13G/A
BlackRock Inc.
8 Jan 24
144
Notice of proposed sale of securities
8 Jan 24
4
JOHN M LEONARD
5 Jan 24
4
David Lebwohl
5 Jan 24
4
Laura Sepp-Lorenzino
5 Jan 24
4
Glenn Goddard
5 Jan 24
4
Derek Hicks
5 Jan 24
4
JAMES BASTA
5 Jan 24
4
Eliana Clark
5 Jan 24
4
Laura Sepp-Lorenzino
3 Jan 24
4
David Lebwohl
3 Jan 24
4
JOHN M LEONARD
3 Jan 24
4
Glenn Goddard
3 Jan 24
144
Notice of proposed sale of securities
7 Dec 23
4
Muna Bhanji
2 Nov 23
4
Muna Bhanji
2 Aug 23
144
Notice of proposed sale of securities
31 Jul 23
4
Muna Bhanji
10 Jul 23
144
Notice of proposed sale of securities
6 Jul 23
4
Eliana Clark
6 Jul 23
4
Eliana Clark
22 Jun 23
144
Notice of proposed sale of securities
20 Jun 23
4
WILLIAM J CHASE
16 Jun 23
4
Frank Verwiel
16 Jun 23
4
Georgia Keresty
16 Jun 23
4
JESSE GOODMAN
16 Jun 23
4
John F Crowley
16 Jun 23
4
Fred E Cohen
16 Jun 23